Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level652 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,842 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT06580574 |
| Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers |
| recruiting |
| Phase 2 |
| 34 |
| Peking UniversityOTHER |
| 1 |
| May 15, 2026 |
| clinicaltrials |
| NCT05702229 | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 163 | AstraZenecaINDUSTRY | 7 | May 14, 2026 | clinicaltrials |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | recruiting | Phase 2 | 180 | I-Mab Biopharma US LimitedINDUSTRY | 3 | May 14, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07007182 | Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer | recruiting | Phase 2 | 54 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07178808 | PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER | recruiting | Phase 2 | 30 | Banner HealthOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06385691 | Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer.(MyDIET) | recruiting | Phase 2 | 60 | Centre Leon BerardOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06846346 | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma(GRACIE) | recruiting | Phase 2 | 88 | UNICANCEROTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer(DUET-GEJ) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07353684 | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer | recruiting | Phase 2 | 49 | Beijing Friendship HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07537348 | Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer(LUCENT-GC-03) | recruiting | Phase 2 | 73 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537361 | Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer(LUCENT-GC-02) | recruiting | Phase 2 | 108 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03259867 | Combination of TATE and PD-1 Inhibitor in Liver Cancer(TATE-PD1) | recruiting | Phase 2 | 54 | Teclison Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03161522 | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05927857 | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | recruiting | Phase 1 / Phase 2 | 45 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05753306 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07517107 | Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer | recruiting | Phase 2 | 600 | Fudan UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07277439 | Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma | recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07320586 | Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer | recruiting | Phase 2 | 40 | Shandong Tumor HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06461910 | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 30 | Zekuan XuOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07072728 | Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | recruiting | Phase 2 | 87 | Psyence Australia Pty LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06055439 | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | recruiting | Phase 1 / Phase 2 | 135 | Chimeric TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05620628 | Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | recruiting | Phase 2 | 25 | Jeeyun LeeOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06468280 | Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer(ROSETTE) | recruiting | Phase 2 | 84 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07354711 | A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3H Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT02584244 | Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | recruiting | Phase 1 / Phase 2 | 66 | Lumicell, Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07110571 | A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer | recruiting | Phase 2 | 200 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07315854 | Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 32 | Beijing Friendship HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07311408 | SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure(SHR-2554) | recruiting | Phase 2 | 40 | Jingdong ZhangOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07289997 | Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) | recruiting | Phase 2 | 39 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT07263386 | A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer(ARTEMIS-GC3) | recruiting | Phase 2 | 460 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259226 | Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers(OASIS) | recruiting | Phase 2 | 400 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06313801 | Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions | recruiting | Phase 2 | 106 | Nizhny Novgorod Regional Clinical Oncology CenterOTHER_GOV | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07149090 | Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites | recruiting | Phase 1 / Phase 2 | 61 | Asan Medical CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06759064 | Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites(IPIZA) | recruiting | Phase 1 / Phase 2 | 24 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06487221 | Avutometinib and Defactinib in Diffuse Gastric Cancer | recruiting | Phase 2 | 27 | Ryan H. Moy, MD, PhDOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07212933 | The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial(RAK in GC) | recruiting | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Oct 8, 2025 | clinicaltrials |
Data updated 22 days agoSource updated May 19, 2026source: clinicaltrials